Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson's Disease

By Neef C.  

Clinical Pharmacokinetics, Vol. 37, Iss. 3, 1999-09 ,pp. : 257-271

Adis International

Access to resources Recommend Favorite

Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease

By Chan Phylinda   Nutt John   Holford Nicholas  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 32, Iss. 3-4, 2005-08 ,pp. : 459-484

Springer Publishing Company

Access to resources Recommend Favorite

Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

By Müller Thomas  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1015-1024

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment

By Reboldi Gianpaolo   Gentile Giorgio   Angeli Fabio   Verdecchia Paolo  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 1, 2011-01 ,pp. : 115-128

Informa Healthcare

Access to resources Recommend Favorite

Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin: Implications for Clinical Practice

By Fareed J.  

Clinical Pharmacokinetics, Vol. 42, Iss. 12, 2003-01 ,pp. : 1043-1057

Adis International

Access to resources Recommend Favorite